DYRK2 and glioma: Likewise, a weaker DYRK2 expression was associated with a worse prognosis in ovarian serous adenocarcinoma [146], CRC [137,145], HCC [138,139], glioma [140] and non-Hodgkin’s lymphoma [136] patients.